Do insulin resistance and hyperinsulinemia drive hepatic VLDL overproduction and create an atherogenic lipoprotein profile?

Under conditions of metabolic dysfunction, the physiologic regulation of hepatic lipid metabolism is severely altered, shifting the cardiovascular risk profile toward accelerated atherogenesis.

Mechanistic pathway of VLDL overproduction

• Loss of physiological inhibition: In healthy, insulin-sensitive states, acute insulin suppresses hepatic very-low-density lipoprotein (VLDL) secretion by limiting free fatty acid (FFA) delivery and promoting intracellular degradation of nascent apolipoprotein B-100 (ApoB).
• Selective insulin resistance: During chronic insulin resistance, the liver remains highly sensitive to insulin-stimulated lipogenesis via the SREBP-1c pathway (driving de novo lipogenesis) while failing to suppress VLDL output.
• Lipid substrate overload: Uncontrolled adipose tissue lipolysis persistently floods the liver with FFAs. This lipid surplus stabilizes nascent ApoB, leading to the excessive assembly and secretion of large, triglyceride-rich VLDL particles.

Formation of an atherogenic lipoprotein profile

• Direct elevation of ApoB: Because each hepatic VLDL particle contains exactly one ApoB-100 molecule, increased VLDL production directly elevates the total circulating ApoB particle count, signaling a high concentration of atherogenic lipoproteins.
• CETP-mediated remodeling: Abundant triglyceride-rich VLDL particles act as substrates for cholesteryl ester transfer protein (CETP), which exchanges triglycerides into LDL and HDL in exchange for cholesteryl esters.
• Generation of small, dense LDL: Subsequent lipolysis of triglyceride-enriched LDL and HDL by hepatic lipase creates small, dense LDL (sdLDL) particles—which are highly susceptible to arterial retention and oxidation—and leads to accelerated clearance of HDL.

Bottom line

• Chronic hyperinsulinemia and insulin resistance drive hepatic VLDL overproduction and elevate circulating ApoB. This process fuels CETP-mediated remodeling, producing a highly atherogenic lipid profile characterized by small, dense LDL and reduced HDL, which markedly increases cardiovascular risk even when standard LDL cholesterol levels appear normal.